Eli Lilly agreed to acquire Merida Biosciences for up to $2.875 billion, aiming to broaden its pipeline beyond obesity. Merida’s approach centers on selectively targeting pathogenic autoantibodies for degradation, with its lead program MER511 in Phase 1 development for Graves’ disease and thyroid eye disease, including the NEXUS trial evaluating safety, tolerability and early pharmacology.